IP Library Patent Application 12587995
Patent Application
App. No. 12/587,995

Methods and compositions for gene inactivation

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/587,995
Abstract

Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.

Claims (19)

1 . A method for inactivating an HIV receptor gene in a subject, the method comprising:

introducing, into a cell of the subject, a homing endonuclease that binds to a target site in an HIV receptor gene and cleaves the HIV receptor gene.

2 . The method of claim 1 , wherein the homing endonuclease is engineered to bind to the target site in the HIV receptor gene.

3 . The method of claim 1 , wherein a polynucleotide encoding the meganuclease is introduced into the cell.

4 . The method of claim 1 , wherein the homing endonuclease is introduced into the cell ex vivo.

5 . The method of claim 1 wherein the homing endonuclease is introduced into the cell in vivo.

6 . The method of claim 3 , wherein the homing endonuclease is introduced into the cell ex vivo.

7 . The method of claims 3 , wherein the homing endonuclease is introduced into the cell in vivo.

8 . The method of claim 1 , wherein the HIV receptor is a CCR-5 receptor.

9 . The method of claim 1 , wherein the HIV receptor is a CXCR4 receptor.

10 . The method of claim 2 wherein the cell is selected from the group consisting of a stem cell, a T-cell, a macrophage, a dendritic cell and an antigen-presenting cell.

11 . The method of claim 1 , wherein the homing endonuclease is selected from the group consisting of I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-TevI, I-TevII and I-TevIII.

12 . The method of claim 9 , wherein the homing endonuclease is SceI or CreI.

13 . A method of treating or preventing HIV infection in a subject, the method comprising:

inactivating an HIV receptor according to the method of claim 1 in a cell isolated from the subject; and

introducing the cell into the subject.

14 . A method of treating or preventing HIV infection in a subject, the method comprising:

introducing the polynucleotide encoding the meganuclease according to claim 7 into a subject; and

inactivating an HIV receptor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2022
From: ANDO, DALE; HOLMES, MICHAEL C.; LEE, GARY KA LEONG
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 060596/0087 →
CHANGE OF NAME Recorded Jul 22, 2022
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 060831/0103 →